Nature publication: antibody therapy controls HIV for months in new clinical trial

Findings from a clinical trial led by Rockefeller University scientists as reported by journal Nature highlight anti-HIV antibodies as a novel treatment option; one that wouldn’t rely on vigilant daily dosing and could potentially reduce the body’s reservoir of HIV, which conventional antiretroviral drugs cannot do. Read the full article here […]

Read More…

RIO trial update

We are delighted to note that we are currently recruiting in all 7 clinical sites across London and Brighton and will shortly be opening 3 new sites at St George’s Hospital in London, Western General Hospital in Edinburgh and North Manchester General Hospital. To date we have recruited and dosed 20 participants into the study. […]

Read More…

RIO trial opens for recruitment

The RIO clinical trial will test whether a new type of therapy can keep HIV under control without daily antiretroviral treatment (ART) tablets. The novel therapy uses a combination of two experimental antibodies (called broadly neutralising monoclonal antibodies, or bNAbs) which have been designed by scientists at the Rockefeller University to target multiple strains of […]

Read More…